Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Inclusion Criteria

• •1. Histologically confirmed NSCLC, with at least one of the known oncogene mutation prior to systemic treatment: EGFR exon 18-21 activating mutation, MET exon-14-skipping mutation, ERBB2 activating mutation, ALK fusion, ROS1 fusion, RET fusion, NTRK1 fusion, NTRK2 fusion, NTRK3 fusion, BRAF V600 mutation, or KRAS G12C mutation
• •2. Patient had received tyrosine kinase inhibitor (TKI) with progressive disease, as assessed by the treating physician
• •3. Had tumor tissue available for DNA extraction and sequencing.
• •4. Eligible for withdrawal of a blood sample for DNA extraction and sequencing.